The Recent Research Analysts' Ratings Changes for Amgen (AMGN)

Lloyd Doyle
October 21, 2017

(AMGN)'s stock declined 9.68%. During the same quarter in the previous year, the company earned $2.84 EPS. About 2.26 million shares traded. The SI to Amgen Incorporated's float is 1%. About 43 shares traded. It has underperformed by 11.43% the S&P500. Amgen Inc. had 66 analyst reports since August 3, 2015 according to SRatingsIntel. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. About 1.51 million shares traded. C R Bard Inc (NYSE:BCR) has risen 40.70% since October 20, 2016 and is uptrending. It has underperformed by 13.70% the S&P500. Krop Julie sold $46,235 worth of stock. Strong Sell. Investors might also notice that two months ago the Buy recommendations (1) outnumbered Sell recommendations (0). Its down 0.10, from 1.25 in 2017Q1.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Lsv Asset reported 1.68M shares or 0.05% of all its holdings. Wells Fargo Mn owns 47,992 shares. Moreover, Summit Creek Advisors Llc has 2.37% invested in the company for 233,380 shares. (NASDAQ:AMGN) for 215,840 shares.

The company is so far trading down by 0.63% percent from yesterday's close.

Pacifica Capital Investments Llc holds 11.8% of its portfolio in Five Below Inc for 466,079 shares. Crestwood Advsrs Grp Incorporated invested in 3,342 shares. Mitchell Mcleod Pugh And Williams accumulated 0.67% or 5,156 shares. Massachusetts Financial Services Company Ma reported 70,058 shares. Cetera has invested 0.76% of its portfolio in AT&T Inc. 240 are owned by Wolverine Asset Management Limited Liability Company. Therefore 30% are positive. After $3.27 actual EPS reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -6.12% negative EPS growth. On Thursday, October 13 the stock rating was initiated by KeyBanc Capital Markets with "Overweight". The stock of AT&T Inc. The firm earned "Buy" rating on Wednesday, August 23 by Oppenheimer. As per Friday, April 1, the company rating was downgraded by Moffet Nathanson. Finally, Morgan Stanley restated an "overweight" rating and issued a $196.00 target price (up previously from $189.00) on shares of Amgen in a research note on Friday, October 6th. The original version of this piece of content can be read at https://www.truebluetribune.com/2017/10/19/investors-buy-amgen-inc-amgn-on-weakness.html. The stock has "Market Perform" rating by Raymond James on Tuesday, September 1. The firm earned "Hold" rating on Monday, June 12 by Jefferies. The firm has "Buy" rating by Jefferies given on Thursday, August 11.

AMAG Pharmaceuticals, Inc.is a pharmaceutical company. The company has market cap of $548.73 million. The Company's offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena; services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.


Since May 24, 2017, it had 0 insider purchases, and 2 insider sales for $1.02 million activity. (NASDAQ:AMGN) shares. 2,922 shares were sold by Patton Cynthia M, worth $451,164. Mengis Capital Management Inc.'s holdings in Amgen were worth $1,048,000 as of its most recent SEC filing. (NASDAQ:AMGN) has "Neutral" rating given on Tuesday, December 20 by Credit Suisse. Rothschild Invest Il invested in 1.24% or 63,521 shares. Its down 0.10, from 1.25 in 2017Q1.

Verity Asset Management Inc increased its stake in Amgen Common (AMGN) by 363.83% based on its latest 2017Q2 regulatory filing with the SEC. 100 funds opened positions while 517 raised stakes. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company's stock valued at $190,000 after buying an additional 7 shares during the period. Commerce National Bank invested 0.37% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Kbc Gru Nv has 0.28% invested in Amgen, Inc. (NASDAQ:AMGN). Legacy Cap Prns stated it has 4,350 shares. Oak Associates Ltd Oh holds 2.8% of its portfolio in Amgen, Inc. Tocqueville Asset Mgmt Ltd Partnership accumulated 88,293 shares. 3,739 were reported by Dillon Inc. Bsw Wealth Ptnrs has invested 0.17% in Amgen, Inc. (NASDAQ:AMGN). 228,829 are owned by Douglass Winthrop Advsr Ltd Liability Corporation. Canandaigua Bank & Trust has 0.26% invested in Amgen, Inc. (NASDAQ:AMGN) for 48,840 shares.

Analysts await Amgen, Inc. (NASDAQ:AMGN) for 168,337 shares. San Francisco Sentry Investment Grp Inc (Ca) reported 0.63% stake. Teacher Retirement Of Texas, Texas-based fund reported 635,893 shares. St Germain D J has 95,713 shares for 2.21% of their portfolio. BMO Capital Markets maintained Amgen, Inc. The company has a market cap of $134.35 billion, a PE ratio of 16.77 and a beta of 1.36. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. Equities research analysts anticipate that Amgen Inc. will post $12.58 earnings per share for the current year. Therefore 50% are positive.

According to Zacks brokerage recommendations, Amgen Inc. The firm has "Buy" rating given on Friday, August 21 by Vetr. (NASDAQ:AMGN) on Tuesday, September 1 with "Market Perform" rating. UBS maintained it with "Buy" rating and $180 target in Thursday, October 29 report. BidaskClub upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Friday, June 23rd. Of all stocks tracked, Amgen had the 7th highest net in-flow for the day.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER